|Mr. Barry Fishman||Chief Exec. Officer, Pres and Director||381.11k||N/A||60|
|Dr. Michael Scott Bumby||Chief Financial Officer||71.54k||N/A||53|
|Mr. Frank Fokkinga||VP of Global Regulatory Affairs, Quality and Compliance||83.6k||N/A||N/A|
|Mr. Frank Rotmann||Head of European Operations and VP||355.51k||N/A||N/A|
|Mr. Geoff Morrow||VP of Bus. Devel.||160.59k||N/A||N/A|
Merus Labs International Inc., a specialty pharmaceutical company, owns, markets, and distributes pharmaceutical products primarily in Europe and Canada. The company offers Elantan, Isoket, and Deponit nitrates for acute and chronic coronary artery disease; Sintrom for the treatment and prevention of thromboembolism diseases; Emselex/Enablex, for the treatment of overactive bladder syndrome; Surgestone and Provames for various health indications in womens; Speciafoldine for macrocytic anemia; and Tredemine for tapeworm. It also provides Salagen for the treatment of symptoms of dry eye and dry mouth disorders, as well as for xerostomia following radiation therapy; Estraderm MX for the treatment of signs and symptoms of estrogen deficiency due to menopause, and for the prevention of accelerated postmenopausal bone loss; and Vancocin for the treatment of gastrointestinal tract bacterial infections. The company is headquartered in Toronto, Canada.
Merus Labs International Inc.’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 6; Compensation: 9.